Novel Sulfones with Antifungal Properties: Antifungal Activities and Interactions with Candida spp. Virulence Factors
-
Published:2018-12-06
Issue:1
Volume:19
Page:12-21
-
ISSN:1389-5575
-
Container-title:Mini-Reviews in Medicinal Chemistry
-
language:en
-
Short-container-title:MRMC
Author:
Gizińska Małgorzata1, Staniszewska Monika1, Ochal Zbigniew2
Affiliation:
1. National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland 2. Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warsaw, Poland
Abstract
Since candidiasis is so difficult to eradicate with an antifungal treatment and the existing antimycotics
display many limitations, hopefully new sulfone derivatives may overcome these deficiencies.
It is pertinent to study new strategies such as sulfone derivatives targeting the virulence attributes
of C. albicans that differentiate them from the host. During infections, the pathogenic potential of
C. albicans relies on the virulence factors as follows: hydrolytic enzymes, transcriptional factors, adhesion,
and development of biofilms. In the article we explored how the above-presented C. albicans fitness
and virulence attributes provided a robust response to the environmental stress exerted by sulfones
upon C. albicans; C. albicans fitness and virulence attributes are fungal properties whose inactivation
attenuates virulence. Our understanding of how these mechanisms and factors are inhibited by sulfones
has increased over the last years. As lack of toxicity is a prerequisite for medical approaches, sulfones
(non-toxic as assessed in vitro and in vivo) may prove to be useful for reducing C. albicans pathogenesis
in humans. The antifungal activity of sulfones dealing with these multiple virulence factors and fitness
attributes is discussed.
Funder
Warsaw University of Technology, Faculty of Chemistry
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology,General Medicine
Reference114 articles.
1. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA. J Clin Microbiol, Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: A 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.,Global Antifungal Surveillance Group, 2010, 48,, 1366-1377, 2. Pfaller MA, Diekema DJ. Crit Rev Microbiol, Epidemiology of invasive mycoses in North America.,, 2010, 36,, 1-53, 3. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Sci Transl Med, Hidden killers: human fungal infections.,, 2012, 4,, 165rv13-, 4. Kołaczkowska A, Kołaczkowski M. J Antimicrob Chemother, Drug resistance mechanisms and their regulation in non-albicans Candida species.,, 2016, 71,, 1438-1450, 5. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ. Clin Infect Dis, Clinical practicce guideline for the management of candidiasis: 2016 update by the Infectious Disease Society of America.,, 2016, 62,, e1-e50,
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|